Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

MediWound (MDWD) Cost of Revenue: 2013-2025

Historic Cost of Revenue for MediWound (MDWD) over the last 13 years, with Sep 2025 value amounting to $4.5 million.

  • MediWound's Cost of Revenue rose 23.25% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year decrease of 1.26%. This contributed to the annual value of $17.6 million for FY2024, which is 16.42% up from last year.
  • Latest data reveals that MediWound reported Cost of Revenue of $4.5 million as of Q3 2025, which was up 3.83% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, MediWound's Cost of Revenue ranged from a high of $5.8 million in Q3 2022 and a low of $3.0 million during Q1 2023.
  • Over the past 3 years, MediWound's median Cost of Revenue value was $4.4 million (recorded in 2024), while the average stood at $4.1 million.
  • Within the past 5 years, the most significant YoY rise in MediWound's Cost of Revenue was 48.15% (2022), while the steepest drop was 36.94% (2022).
  • MediWound's Cost of Revenue (Quarterly) stood at $5.5 million in 2021, then plummeted by 36.94% to $3.5 million in 2022, then spiked by 33.50% to $4.6 million in 2023, then climbed by 6.88% to $4.9 million in 2024, then increased by 23.25% to $4.5 million in 2025.
  • Its Cost of Revenue stands at $4.5 million for Q3 2025, versus $4.4 million for Q2 2025 and $3.2 million for Q1 2025.